Khavinson short peptide bioregulator (cartilage-targeted)
Cartalax
Research use only
Written by pep4U Editorial Team · Last reviewed July 8, 2026
A very short synthetic peptide (Ala-Glu-Asp-Lys) from the Russian Khavinson bioregulator family, researched for cartilage and joint health.
| Class / type | Khavinson short peptide bioregulator (cartilage-targeted) |
|---|
| Category | Longevity & Cellular |
|---|
| Status (Jul 2026) | Research use only |
|---|
How it works
The proposed mechanism is epigenetic: the peptide is thought to enter cells and bind DNA in chondrocytes, modulating expression of genes involved in collagen II synthesis and matrix regulation.
Known / used for
Researched and marketed abroad for joint and cartilage support, musculoskeletal aging, and connective tissue repair.
Positives
Reported in Russian studies to support cartilage regeneration and reduce age-related joint decline; peptide is small and reported to be well tolerated.
Negatives & risks
Evidence is almost entirely Russian observational and animal data with essentially no independent Western clinical trials; efficacy in humans is unproven; purity and sourcing are unregulated.
What people like most (reported community sentiment - not endorsement)
Bioregulator enthusiasts report subjective joint comfort, though sentiment rests on anecdote rather than controlled data.
Frequently asked questions
What is Cartalax?
A very short synthetic peptide (Ala-Glu-Asp-Lys) from the Russian Khavinson bioregulator family, researched for cartilage and joint health. The proposed mechanism is epigenetic: the peptide is thought to enter cells and bind DNA in chondrocytes, modulating expression of genes involved in collagen II synthesis and matrix regulation.
What is Cartalax used or researched for?
Researched and marketed abroad for joint and cartilage support, musculoskeletal aging, and connective tissue repair.
Is Cartalax FDA-approved or legal?
NOT FDA-approved and not recognized as a drug in the United States; sold only as a research or supplement-grade compound not authorized for human treatment.
What are the main risks or downsides of Cartalax?
Evidence is almost entirely Russian observational and animal data with essentially no independent Western clinical trials; efficacy in humans is unproven; purity and sourcing are unregulated.
Legal / regulatory status
NOT FDA-approved and not recognized as a drug in the United States; sold only as a research or supplement-grade compound not authorized for human treatment.
Recommended supplies
See all supplies →As an Amazon Associate we earn from qualifying purchases.
← Back to Longevity & Cellular